Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models

Cannabinoid receptor 1 (CB1 receptor) controls several neuronal functions, including neurotransmitter release, synaptic plasticity, gene expression and neuronal viability. Downregulation of CB1 expression in the basal ganglia of patients with Huntington's disease (HD) and animal models represents one of the earliest molecular events induced by mutant huntingtin (mHtt). This early disruption of neuronal CB1 signaling is thought to contribute to HD symptoms and neurodegeneration. Here we determined whether CB1 downregulation measured in patients with HD and mouse models was ubiquitous or restricted to specific striatal neuronal subpopulations. Using unbiased semi‐quantitative immunohistochemistry, we confirmed previous studies showing that CB1 expression is downregulated in medium spiny neurons of the indirect pathway, and found that CB1 is also downregulated in neuropeptide Y (NPY)/neuronal nitric oxide synthase (nNOS)‐expressing interneurons while remaining unchanged in parvalbumin‐ and calretinin‐expressing interneurons. CB1 downregulation in striatal NPY/nNOS‐expressing interneurons occurs in R6/2 mice, HdhQ150/Q150 mice and the caudate nucleus of patients with HD. In R6/2 mice, CB1 downregulation in NPY/nNOS‐expressing interneurons correlates with diffuse expression of mHtt in the soma. This downregulation also occludes the ability of cannabinoid agonists to activate the pro‐survival signaling molecule cAMP response element‐binding protein in NPY/nNOS‐expressing interneurons. Loss of CB1 signaling in NPY/nNOS‐expressing interneurons could contribute to the impairment of basal ganglia functions linked to HD.

[1]  Masahiko Watanabe,et al.  Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease , 2012, Neurobiology of Disease.

[2]  J. Tepper,et al.  A Novel Functionally Distinct Subtype of Striatal Neuropeptide Y Interneuron , 2011, The Journal of Neuroscience.

[3]  B. Shaby,et al.  Identifying polyglutamine protein species in situ that best predict neurodegeneration , 2011, Nature chemical biology.

[4]  E. Abercrombie,et al.  In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease , 2011, Front. Syst. Neurosci..

[5]  J. Tepper,et al.  Heterogeneity and Diversity of Striatal GABAergic Interneurons , 2010, Front. Neuroanat..

[6]  I. Bezprozvanny,et al.  Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. , 2010, Future neurology.

[7]  Koen Van Laere,et al.  Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo , 2010, The Journal of Nuclear Medicine.

[8]  B. Hudson,et al.  Physical and functional interaction between CB1 cannabinoid receptors and β2‐adrenoceptors , 2010, British journal of pharmacology.

[9]  Carlos Cepeda,et al.  Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease , 2010, ASN neuro.

[10]  Anatol C. Kreitzer,et al.  Distinct Roles of GABAergic Interneurons in the Regulation of Striatal Output Pathways , 2010, The Journal of Neuroscience.

[11]  L. Raymond,et al.  Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.

[12]  L. Raymond,et al.  Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.

[13]  Michael R. Hayden,et al.  Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin , 2009, Nature Medicine.

[14]  A. Hannan,et al.  Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease , 2009, Neuroscience.

[15]  Anatol C. Kreitzer,et al.  Physiology and pharmacology of striatal neurons. , 2009, Annual review of neuroscience.

[16]  M. Isokawa.  Time-dependent induction of CREB phosphorylation in the hippocampus by the endogenous cannabinoid , 2009, Neuroscience Letters.

[17]  Y. Ben-Ari,et al.  Dopamine-Deprived Striatal GABAergic Interneurons Burst and Generate Repetitive Gigantic IPSCs in Medium Spiny Neurons , 2009, The Journal of Neuroscience.

[18]  J. Fernández-Ruiz.  The endocannabinoid system as a target for the treatment of motor dysfunction , 2009, British journal of pharmacology.

[19]  J. Tsien,et al.  In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease , 2009, The Journal of Neuroscience.

[20]  L. Goldstein,et al.  Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin , 2008, The Journal of Neuroscience.

[21]  A. Parent,et al.  The fate of the large striatal interneurons expressing calretinin in Huntington’s disease , 2008, Neuroscience Research.

[22]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[23]  Michela Matteoli,et al.  Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity , 2007, Science.

[24]  Michelle K. Lupton,et al.  The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes , 2007, Brain Research Bulletin.

[25]  Masahiko Watanabe,et al.  Subcellular Arrangement of Molecules for 2-Arachidonoyl-Glycerol-Mediated Retrograde Signaling and Its Physiological Contribution to Synaptic Modulation in the Striatum , 2007, The Journal of Neuroscience.

[26]  T. Freund,et al.  Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia , 2006, Neuroscience.

[27]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[28]  Masahiko Watanabe,et al.  Depolarization‐induced suppression of inhibition mediated by endocannabinoids at synapses from fast‐spiking interneurons to medium spiny neurons in the striatum , 2006, The European journal of neuroscience.

[29]  E. S. Graham,et al.  Induction of Krox-24 by Endogenous Cannabinoid Type 1 Receptors in Neuro2A Cells Is Mediated by the MEK-ERK MAPK Pathway and Is Suppressed by the Phosphatidylinositol 3-Kinase Pathway* , 2006, Journal of Biological Chemistry.

[30]  R. Wightman,et al.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.

[31]  Carlos Cepeda,et al.  Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. , 2006, Journal of neurophysiology.

[32]  Anatol C. Kreitzer,et al.  Dopamine Modulation of State-Dependent Endocannabinoid Release and Long-Term Depression in the Striatum , 2005, The Journal of Neuroscience.

[33]  E Sylvester Vizi,et al.  Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis , 2005, The Journal of Neuroscience.

[34]  Carlos Cepeda,et al.  Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.

[35]  Haibei Hu,et al.  Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. , 2004, European journal of biochemistry.

[36]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[37]  G. Bernardi,et al.  Immunolocalization of CB1 receptor in rat striatal neurons: A confocal microscopy study , 2004, Synapse.

[38]  J. Littleton,et al.  Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[40]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[41]  Richard G. Brusch,et al.  Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.

[42]  J. Girault,et al.  Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus , 2003, The Journal of Neuroscience.

[43]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[44]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[45]  H. Bading,et al.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.

[46]  N. Stella,et al.  Receptor-dependent formation of endogenous cannabinoids in cortical neurons. , 2001, European journal of pharmacology.

[47]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[48]  H. Robertson,et al.  Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice , 2000, Neuroscience.

[49]  M. Herkenham,et al.  Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double‐label in situ hybridization study , 2000 .

[50]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[51]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[52]  S. Finkbeiner.  CREB Couples Neurotrophin Signals to Survival Messages , 2000, Neuron.

[53]  G P Bates,et al.  Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. , 1999, Human molecular genetics.

[54]  L. Parsons,et al.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.

[55]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[56]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[57]  P. Casellas,et al.  Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.

[58]  M. Herkenham,et al.  Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus , 1994, Annals of neurology.

[59]  R. Faull,et al.  Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.

[60]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[61]  M. Burnier,et al.  Production and characterization of four anti-neuropeptide Y monoclonal antibodies. , 1992, Hybridoma.

[62]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[63]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[64]  P. Emson,et al.  Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease , 1985, Brain Research.

[65]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[66]  J. Lucas,et al.  Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. , 2011, Brain : a journal of neurology.

[67]  T. Rubino,et al.  Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. , 2006, Molecular neurobiology.

[68]  Wolfgang Schmid,et al.  Disruption of CREB function in brain leads to neurodegeneration , 2002, Nature Genetics.

[69]  D. Lovinger,et al.  CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.

[70]  M. Herkenham,et al.  Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. , 2000, Synapse.

[71]  Alcino J. Silva,et al.  CREB and memory. , 1998, Annual review of neuroscience.